文献速递糖尿病

西格列汀用于普通内科和外科2型糖尿病住院患者血糖管理的疗效(Sita-Hospital):一项多中心、前瞻性、开放标签、非劣效性随机试验

Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2016-12-08

这项在美国5家医院开展的多中心、前瞻性、开放标签、非劣效性随机试验纳入279例普通内科和外科住院的2型糖尿病患者,比较西格列汀联合基础胰岛素与基础-餐时胰岛素方案。结果显示,西格列汀-基础组的平均每日血糖浓度9.5 mmol/L(SD 2.7)不劣于基础-餐时组的9.4 mmol/L(SD 2.7),平均血糖差异为0.1 mmol/L(95%CI -0.6至0.7)。两组治疗失败率和低血糖发生率均无显著差异。

要点

  • 西格列汀联合基础胰岛素方案在普通内科和外科住院2型糖尿病患者中,平均每日血糖浓度不劣于基础-餐时胰岛素方案。
  • 西格列汀-基础组治疗失败率16%、低血糖9%,与基础-餐时组的19%和12%相比均无显著差异。
  • 西格列汀联合基础胰岛素可作为非重症监护环境下住院2型糖尿病患者高血糖管理的便捷替代方案。

核心结论

  • 西格列汀联合基础胰岛素方案在普通内科和外科住院2型糖尿病患者中,平均每日血糖浓度不劣于基础-餐时胰岛素方案,且安全性和有效性相当,是劳动密集型基础-餐时胰岛素方案的便捷替代选择。

研究设计与样本

  • 多中心、前瞻性、开放标签、非劣效性随机临床试验(Sita-Hospital),在美国5家医院开展。
  • 纳入年龄18-80岁、随机血糖7.8-22.2 mmol/L、接受饮食或口服降糖药治疗或每日胰岛素总量≤0.6单位/公斤的普通内科和外科住院2型糖尿病患者。
  • 共招募279例患者,277例随机分配至治疗:西格列汀-基础组138例,基础-餐时组139例。
  • 随机分组按随机血糖浓度(高于或低于11.1 mmol/L)进行区组分层,采用计算机生成表格1:1分配。
  • 主要终点为治疗前10天内每日血糖浓度均值的组间差异非劣效性(非劣效界值为差异<1 mmol/L)。

主要发现

  • 西格列汀-基础组平均每日血糖浓度为9.5 mmol/L(SD 2.7),基础-餐时组为9.4 mmol/L(SD 2.7),平均血糖差异为0.1 mmol/L(95%CI -0.6至0.7)。
  • 住院时间两组相似:西格列汀-基础组中位4天(IQR 3-8),基础-餐时组中位4天(IQR 3-8),p=0.54。
  • 治疗失败在西格列汀-基础组发生22例(16%),基础-餐时组26例(19%),p=0.54。
  • 低血糖在西格列汀-基础组发生13例(9%),基础-餐时组17例(12%),p=0.45。
  • 急性肾损伤在西格列汀-基础组发生7例(5%),基础-餐时组6例(4%);急性胰腺炎1例(0.7%)发生在基础-餐时组;本试验无死亡发生。

关键数值与推荐

  • 非劣效性界值为平均每日血糖浓度组间差异<1 mmol/L。
  • 主要终点达到非劣效性阈值,因两组平均每日血糖浓度无显著差异。

临床怎么用

  • 作者认为,对于非重症监护环境下普通内科和外科住院的2型糖尿病患者,西格列汀联合基础胰岛素方案在管理高血糖方面与基础-餐时胰岛素方案同样有效和安全,且是后者的便捷替代方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of incretin-based drugs in the treatment of patients with type 2 diabetes admitted to hospital has not been extensively assessed. In this study, we compared the safety and efficacy of a dipeptidyl peptidase-4 inhibitor (sitagliptin) plus basal insulin with a basal-bolus insulin regimen for the management of patients with type 2 diabetes in general medicine and surgery in hospitals. METHODS: We did a multicentre, prospective, open-label, non-inferiority randomised clinical trial (Sita-Hospital) in five hospitals in the USA, enrolling patients aged 18-80 years with type 2 diabetes and a random blood glucose concentration of 7·8-22·2 mmol/L who were being treated with diet or oral antidiabetic drugs or had a total daily insulin dose of 0·6 units per kg or less, admitted to general medicine and surgery services. We randomly assigned patients (1:1) to receive either sitagliptin plus basal glargine once daily (the sitagliptin-basal group) or a basal-bolus regimen with glargine once daily and rapid-acting insulin lispro or aspart before meals (the basal-bolus group) during the hospital stay. All other antidiabetic drugs were discontinued on admission. The randomisation was achieved by computer-generated tables with block stratification according to randomisation blood glucose concentrations (ie, higher or lower than 11·1 mmol/L). The primary endpoint of the trial was non-inferiority in mean differences between groups in their daily blood glucose concentrations during the first 10 days of therapy (point-of-care measurements; non-inferiority was deemed a difference <1 mmol/L). The safety endpoints included hypoglycaemia and uncontrolled hyperglycaemia leading to treatment failure. All participants who received at least one dose of study drug were included in the analysis. This study is registered with ClinicalTrials.gov, number NCT01845831. FINDINGS: Between Aug 23, 2013, and July 27, 2015, we recruited 279 patients, and randomly assigned 277 to treatment; 138 to sitagliptin-basal and 139 to basal-bolus. The length of stay in hospital was similar for both groups (median 4 days [IQR 3-8] vs 4 [3-8] days, p=0·54). The mean daily blood glucose concentration in the sitagliptin-basal group (9·5 mmol/L [SD 2·7]) was not inferior to that in the basal-bolus group 9·4 mmol/L [2·7]) with a mean blood glucose difference of 0·1 mmol/L (95% CI -0·6 to 0·7). No deaths occurred in this trial. Treatment failure occurred in 22 patients (16%) in the sitagliptin-basal group versus 26 (19%) in the basal-bolus group (p=0·54). Hypoglycaemia occurred in 13 patients (9%) in the sitagliptin-basal group and in 17 (12%) in the basal-bolus group (p=0·45). No differences in hospital complications were noted between groups. Seven patients (5%) developed acute kidney injury in the sitagliptin-basal group and six (4%) in the basal-bolus group. One patient (0·7%) developed acute pancreatitis (in the basal-bolus group). INTERPRETATION: The trial met the non-inferiority threshold for the primary endpoint, because there was no significant difference between groups in mean daily blood glucose concentrations. Treatment with sitagliptin plus basal insulin is as effective and safe as, and a convenient alternative to, the labour-intensive basal-bolus insulin regimen for the management of hyperglycaemia in patients with type 2 diabetes admitted to general medicine and surgery services in hospital in the non-intensive-care setting. FUNDING: Merck.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Pasquel FJ, Gianchandani R, Rubin DJ, et al. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2016. PMID: 27964837. doi:10.1016/S2213-8587(16)30402-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。